title: Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors.
abstract: BACKGROUND
  As the number of patients on the United States kidney transplant list increases, investigation into the utility of transplanting organs formerly considered marginal or undesirable has intensified. Using kidneys from hepatitis B surface antigen (HBsAg)-positive donors is thought to place recipients at excessive risk of graft failure, morbidity, and mortality. However, the risks of using kidneys from HBsAg-negative but hepatitis B core antibody (HBcAb)-positive donors have not been defined.
  
  
  METHODS
  Between 1990 and 1994, our group transplanted 1067 cadaveric kidneys, including 38 from HBsAg(-)/HBcAb(+) donors. Of these 38 kidneys, 27 were transplanted into HBcAb(-) recipients (group 1) and 11 were transplanted into HBcAb(+) recipients (group 2). Group 1 and 2 patients received no hepatitis immunoglobulin therapy after transplantation and received the same immunosuppression and rejection therapies as recipients of kidneys from HBcAb(-) donors.
  
  
  RESULTS
  After transplantation, none of the group 1 patients became HBsAg(+), three became hepatitis B surface antibody (HBsAb)-positive, and two became HBcAb(+). Of the group 2 patients, none became newly HBsAg(+) or HBsAb(+). No patient receiving a kidney from an HBsAg(-)/HBcAb(+) donor developed signs or symptoms of clinical hepatitis B. Graft and patient survival rates were similar in both groups and similar to the rates of the 1029 recipients of kidneys from HBcAb(-) donors.
  
  
  CONCLUSIONS
  Recipients of kidneys from HBsAg(-)/HBcAb(+) donors are at a small risk of hepatitis B seroconversion but are at no excess risk of graft failure or short-term morbidity or mortality.
authors.affiliation: National Institute of Transplantation, Los Angeles, California 90057, USA.
authors.forename: R
authors.initials: R
authors.lastname: Satterthwaite
authors.forename: I
authors.initials: I
authors.lastname: Ozgu
authors.forename: H
authors.initials: H
authors.lastname: Shidban
authors.forename: S
authors.initials: S
authors.lastname: Aswad
authors.forename: V
authors.initials: V
authors.lastname: Sunga
authors.forename: R
authors.initials: R
authors.lastname: Zapanta
authors.forename: P
authors.initials: P
authors.lastname: Asai
authors.forename: T
authors.initials: T
authors.lastname: Bogaard
authors.forename: U
authors.initials: U
authors.lastname: Khetan
authors.forename: R G
authors.initials: RG
authors.lastname: Mendez
authors.forename: R
authors.initials: R
authors.lastname: Mendez
mesh_terms: D000328:Adult; D002102:Cadaver; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000592:standards*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014019:Tissue Donors / Q000706:statistics & numerical data; D009927:Tissue and Organ Procurement / Q000379:methods
chemical_list: D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens